Long-term outcome of omalizumab-assisted desensitisation to cows milk and eggs in patients refractory to conventional oral immunotherapy: real-life study
Allergol. immunopatol
; 50(3): 1-7, 2022. tab, graf
Artigo
em Inglês
| IBECS
| ID: ibc-203445
Biblioteca responsável:
ES1.1
Localização: ES15.1 - BNCS
ABSTRACT
Background:
Oral immunotherapy (OIT) is a promising approach to cows milk and egg aller-gies, but reactions are frequent and some patients cannot be desensitized.Objective:
To evaluate long-term OIT outcomes with omalizumab (OMZ) in paediatric patients with severe egg and/or milk allergies.Methods:
This retrospective real-life study analysed findings in children with Immunoglobulin E-mediated allergy to cows milk and/or hen eggs refractory to conventional OIT, who under-went OIT with OMZ in our department between 1 January 2010 and 31 December 2015.Results:
In all, 41 patients were included (median age 7 years; interquartile range [IQR] 5.59.5); 26/41 (63.4%) underwent OIT for milk, 8/41 (19.5%) for egg and 7/41 (17.1%) for both. The median time between initiation of OMZ and OIT was 27 weeks (IQR 2233). Forty (97.56%) patients reached the maintenance phase (200 mL of cows milk and 30 mL of raw egg or 1 cooked egg) in a median time of 27 weeks (IQR 1837). The median total time with OMZ was 117 weeks (IQR 88144). During the OMZ period, 2.44% (1/41) of patients presented anaphy-laxis. After discontinuation of OMZ, 29.3% (12/41) presented anaphylaxis, 50% of them had a poor adherence to daily ingestion. One patient (2.44%) was diagnosed with eosinophilic esoph-agitis after 2 years of discontinuation of OMZ. Currently, after a median time of 9 years (IQR 710) since the initiation of OMZ, 75.6% (31/41) are desensitized (27/31 without OMZ).Conclusions:
Omalizumab allows desensitisation of children with severe allergies to cows milk and/or egg without developing severe reactions while receiving this treatment. However, dis-continuation of OMZ leads to severe allergic reactions, and hence must be monitored carefully.© 2022 Codon Publications. Published by Codon Publications (AU)
Texto completo:
Disponível
Coleções:
Bases de dados nacionais
/
Espanha
Base de dados:
IBECS
Assunto principal:
Hipersensibilidade a Leite
/
Antialérgicos
/
Hipersensibilidade a Ovo
/
Omalizumab
/
Anafilaxia
Limite:
Criança
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Allergol. immunopatol
Ano de publicação:
2022
Tipo de documento:
Artigo
Instituição/País de afiliação:
Universitat Autònoma de Barcelona/España